Long-term effects of levamisole treatment in childhood nephrotic syndrome

Viktória Sümegi, Ibolya Haszon, Béla Iványi, Csaba Bereczki, Ferenc Papp, Sándor Túri

Research output: Contribution to journalArticle

Abstract

The effects of levamisole treatment on long-term outcome were evaluated in a retrospective study of frequently-relapsing (FRNS, n=15), steroid-dependent (SDNS, n=13), and steroid-resistant (SRNS, n=6) nephrotic syndrome in 34 children (21 boys, 13 girls, mean age 5.0±3.4 years) during a 60-month follow-up period. The definition of frequent relapses was ≥4 relapses per year. The current relapse was treated with prednisolone 60 mg/m2 per day for 4 weeks, then with 40 mg/m2 every other day for 4 weeks, after which the dose was tapered by 10 mg weekly. From the beginning of the 5th week, levamisole was introduced at a dose of 2 mg/kg per day. The duration of levamisole treatment was 17±7 months. Before starting levamisole treatment the mean level of proteinuria was 2.17±1.34 g/day and the relapse rate was 4.41/year. By the end of levamisole therapy, proteinuria had fallen to 0.142±0.211 g/day and the relapse rate to 0.41/year. No relapse occurred in 23 of the 34 patients during levamisole treatment. In the 24-month follow-up period after the discontinuation of levamisole, 28 children remained in total remission, while 6 had relapses. The cumulative steroid dose before levamisole therapy was 7,564.4±3,497.1 mg/year and following the introduction of levamisole 1,472.9±1,729.9 mg/year (P

Original languageEnglish
Pages (from-to)1354-1360
Number of pages7
JournalPediatric Nephrology
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 2004

Fingerprint

Levamisole
Nephrotic Syndrome
Recurrence
Therapeutics
Steroids
Proteinuria
Prednisolone
Retrospective Studies

Keywords

  • Cumulative steroid dose
  • Levamisole
  • Nephrotic syndrome
  • Prednisolone
  • Relapse rate

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Long-term effects of levamisole treatment in childhood nephrotic syndrome. / Sümegi, Viktória; Haszon, Ibolya; Iványi, Béla; Bereczki, Csaba; Papp, Ferenc; Túri, Sándor.

In: Pediatric Nephrology, Vol. 19, No. 12, 12.2004, p. 1354-1360.

Research output: Contribution to journalArticle

@article{29dad011eb034576b6a1f13402ad31bf,
title = "Long-term effects of levamisole treatment in childhood nephrotic syndrome",
abstract = "The effects of levamisole treatment on long-term outcome were evaluated in a retrospective study of frequently-relapsing (FRNS, n=15), steroid-dependent (SDNS, n=13), and steroid-resistant (SRNS, n=6) nephrotic syndrome in 34 children (21 boys, 13 girls, mean age 5.0±3.4 years) during a 60-month follow-up period. The definition of frequent relapses was ≥4 relapses per year. The current relapse was treated with prednisolone 60 mg/m2 per day for 4 weeks, then with 40 mg/m2 every other day for 4 weeks, after which the dose was tapered by 10 mg weekly. From the beginning of the 5th week, levamisole was introduced at a dose of 2 mg/kg per day. The duration of levamisole treatment was 17±7 months. Before starting levamisole treatment the mean level of proteinuria was 2.17±1.34 g/day and the relapse rate was 4.41/year. By the end of levamisole therapy, proteinuria had fallen to 0.142±0.211 g/day and the relapse rate to 0.41/year. No relapse occurred in 23 of the 34 patients during levamisole treatment. In the 24-month follow-up period after the discontinuation of levamisole, 28 children remained in total remission, while 6 had relapses. The cumulative steroid dose before levamisole therapy was 7,564.4±3,497.1 mg/year and following the introduction of levamisole 1,472.9±1,729.9 mg/year (P",
keywords = "Cumulative steroid dose, Levamisole, Nephrotic syndrome, Prednisolone, Relapse rate",
author = "Vikt{\'o}ria S{\"u}megi and Ibolya Haszon and B{\'e}la Iv{\'a}nyi and Csaba Bereczki and Ferenc Papp and S{\'a}ndor T{\'u}ri",
year = "2004",
month = "12",
doi = "10.1007/s00467-004-1608-8",
language = "English",
volume = "19",
pages = "1354--1360",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Long-term effects of levamisole treatment in childhood nephrotic syndrome

AU - Sümegi, Viktória

AU - Haszon, Ibolya

AU - Iványi, Béla

AU - Bereczki, Csaba

AU - Papp, Ferenc

AU - Túri, Sándor

PY - 2004/12

Y1 - 2004/12

N2 - The effects of levamisole treatment on long-term outcome were evaluated in a retrospective study of frequently-relapsing (FRNS, n=15), steroid-dependent (SDNS, n=13), and steroid-resistant (SRNS, n=6) nephrotic syndrome in 34 children (21 boys, 13 girls, mean age 5.0±3.4 years) during a 60-month follow-up period. The definition of frequent relapses was ≥4 relapses per year. The current relapse was treated with prednisolone 60 mg/m2 per day for 4 weeks, then with 40 mg/m2 every other day for 4 weeks, after which the dose was tapered by 10 mg weekly. From the beginning of the 5th week, levamisole was introduced at a dose of 2 mg/kg per day. The duration of levamisole treatment was 17±7 months. Before starting levamisole treatment the mean level of proteinuria was 2.17±1.34 g/day and the relapse rate was 4.41/year. By the end of levamisole therapy, proteinuria had fallen to 0.142±0.211 g/day and the relapse rate to 0.41/year. No relapse occurred in 23 of the 34 patients during levamisole treatment. In the 24-month follow-up period after the discontinuation of levamisole, 28 children remained in total remission, while 6 had relapses. The cumulative steroid dose before levamisole therapy was 7,564.4±3,497.1 mg/year and following the introduction of levamisole 1,472.9±1,729.9 mg/year (P

AB - The effects of levamisole treatment on long-term outcome were evaluated in a retrospective study of frequently-relapsing (FRNS, n=15), steroid-dependent (SDNS, n=13), and steroid-resistant (SRNS, n=6) nephrotic syndrome in 34 children (21 boys, 13 girls, mean age 5.0±3.4 years) during a 60-month follow-up period. The definition of frequent relapses was ≥4 relapses per year. The current relapse was treated with prednisolone 60 mg/m2 per day for 4 weeks, then with 40 mg/m2 every other day for 4 weeks, after which the dose was tapered by 10 mg weekly. From the beginning of the 5th week, levamisole was introduced at a dose of 2 mg/kg per day. The duration of levamisole treatment was 17±7 months. Before starting levamisole treatment the mean level of proteinuria was 2.17±1.34 g/day and the relapse rate was 4.41/year. By the end of levamisole therapy, proteinuria had fallen to 0.142±0.211 g/day and the relapse rate to 0.41/year. No relapse occurred in 23 of the 34 patients during levamisole treatment. In the 24-month follow-up period after the discontinuation of levamisole, 28 children remained in total remission, while 6 had relapses. The cumulative steroid dose before levamisole therapy was 7,564.4±3,497.1 mg/year and following the introduction of levamisole 1,472.9±1,729.9 mg/year (P

KW - Cumulative steroid dose

KW - Levamisole

KW - Nephrotic syndrome

KW - Prednisolone

KW - Relapse rate

UR - http://www.scopus.com/inward/record.url?scp=8844221152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844221152&partnerID=8YFLogxK

U2 - 10.1007/s00467-004-1608-8

DO - 10.1007/s00467-004-1608-8

M3 - Article

VL - 19

SP - 1354

EP - 1360

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 12

ER -